(Reuters) -China is planning to authorize the COVID-19 vaccine developed by Germany’s BioNTech SE by July, the Wall Street Journal reported on Friday, citing people familiar with the matter.
If approved, it would become the first foreign COVID-19 vaccine to be authorized in the country.
Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks, the report said.
BioNTech said in a statement that it does not speculate on timings of approvals.
The National Health Commission of China and Shanghai Fosun Pharmaceutical Group Co Ltd, which signed a potential supply deal with the German drugmaker in August for the vaccine, did not immediately respond to Reuters requests for comment. (https://reut.rs/2Q8psHJ)
The vaccine, developed in collaboration with Pfizer Inc, is already approved in several countries, including the United States, the United Kingdom and Israel.
U.S.-listed shares of BioNTech were up 3.3% at $145.4 on Friday.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)
